What is our Investment Case?

In becoming the trusted global leader in access to medicines, the Group has consistently delivered healthy financial returns. We believe there are several reasons to invest in Clinigen.

UNIQUE AND DIVERSE BUSINESS MODEL

We offer access to medicines at the key stages of the pharmaceutical product lifecycle by utilising Clinigen’s balanced portfolio, across the services and products businesses.

GLOBAL CAPABILITY

We have built a global supply chain and distribution network, organically, through acquisitions and partnerships, providing local market knowledge supported by global expertise.

INTERNATIONAL LOCATIONS 14
COUNTRIES SUPPLIED IN LAST THREE YEARS 129
EXPERIENCED MANAGEMENT TEAM

We have an experienced management team both at the regional and Group level, with a track record of delivering strong growth every year since inception.

MARKET-LEADING POSITIONS

We are the global leader in the management of early access programs to innovative new medicines. We are a global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials (‘IITs’).

Position

#1

DISCIPLINED CORPORATE AND PRODUCT ACQUISITIONS

We have made a number of acquisitions, both of corporates to build out the infrastructure platform, and of niche hospital speciality medicines. Both have contributed towards double-digit EPS growth since IPO in 2012.

CORPORATE ACQUISITIONS SINCE IPO IN 2012 6
PRODUCT ACQUISITIONS SINCE IPO IN 2012 6
BROAD CLIENT AND CUSTOMER BASE

We have deep, well-established relationships with pharmaceutical and biotech companies as clients and Healthcare professionals (‘HCPs’) as customers.

NUMBER OF PHARMACEUTICAL AND BIOTECH COMPANIES AS CLIENTS 532
HCPS AS CUSTOMERS* 15,580

*HCPs as customers indicates the number of registered users on Cliniport

SIGNIFICANT LONG-TERM GROWTH POTENTIAL

We have an increasing exposure to emerging pharmaceutical growth markets by building out our infrastructure platform, service capability and product offering through a combination of organic and acquisitional growth.

HIGHLY CASH GENERATIVE

We generate strong cash returns which are underpinned by strong credit control and working capital management.

2. Operating cash flow is net cash flow from operating activities before income taxes and interest.